国产硫酸氯吡格雷片降低血小板聚集率的临床观察

Clinical trial of evaluating the efficacy of clopidogrel on anti platelet aggregation

目的 :比较国产氯吡格雷片 ( CPG)和噻氯吡啶片 ( TCP)降低血小板聚集率的疗效和安全性。方法 :2 40例高血小板聚集率的患者随机分为 CPG组 ( CPG 5 0 mg)和 TCP组 ( TCP 2 5 0 m g)进行双盲、对照治疗 4wk,观察治疗前后血小板聚集率的变化和不良反应。结果 :CPG组和 TCP组降低血小板聚集率的疗效相同 [二磷酸腺苷 ( ADP) 0 .5︼mol/ L诱导 ,CPG组降低2 8.8% ,TCP组降低 32 .8% ,P=0 .2 3;ADP 1.0︼mol/ L诱导 ,CPG组降低 34 .3% ,TCP组降低 37.2 % ,P=0 .42 ]。 CPG组的不良反应较少。结论 :国产 CPG( 5 0 m g)与 TCP( 2 5 0 m g)有等效的抗血小板聚集作用 。

AIM: To compare the efficacy and safety of clopidogrel on anti platelet aggregation with ticlopidine. METHODS: There were 240 patients with high platelet aggregation randomized into clopidogrel group (CPG group: CPG 50 mg) and ticlopidine group (TCP group: TCP 250 mg), given double blinded and controlled treatment for 4 wk, evaluated the change of platelet aggregation and adverse drug reaction. RESULTS: The anti platelet aggregation effects of CPG and TCP were similar (ADP 0 5 μmol/L induced, 28 8% vs 32 8%, P= 0 23; ADP 1 0 μmol/L induced, 34 3% vs 37 2%, P =0 42). CONCLUSION: The anti platelet aggregation effect of clopidogrel is similar to that of ticlopidine. Clopidogrel is of less adverse drug reaction.